|25th June,2019||12 am||Track 1|
Start-ups with new medical technology on the market are becoming overpriced. Therefore, large and mid-size companies are showing a growing interest for earlier stage MedTech companies through R&D collaboration and licensing deals when looking outside for new R&D. Which strategies are those companies pursuing? Is there a difference of pattern between big and mid-size companies approaches when dealing with early stage investment and assets?